Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor
Status:
RECRUITING
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies aim to evaluate the initial efficacy of leflunomide tablets in second-line treatment of advanced MEN-1 neuroendocrine tumors, and to provide evidence for phase III clinical trials.
Phase:
PHASE2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences